Literature DB >> 28656462

A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.

Li Zhang1,2, Min Tang2, Sipan Chen1,2, Xiaoyan Lei2, Xiaoling Zhang2, Yi Huan3.   

Abstract

OBJECTIVES: This meta-analysis was undertaken to review the diagnostic accuracy of PI-RADS V2 for prostate cancer (PCa) detection with multiparametric MR (mp-MR).
METHODS: A comprehensive literature search of electronic databases was performed by two observers independently. Inclusion criteria were original research using the PI-RADS V2 system in reporting prostate MRI. The methodological quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Data necessary to complete 2 × 2 contingency tables were obtained from the included studies.
RESULTS: Thirteen studies (2,049 patients) were analysed. This is an initial meta-analysis of PI-RADs V2 and the overall diagnostic accuracy in diagnosing PCa was as follows: pooled sensitivity, 0.85 (0.78-0.91); pooled specificity, 0.71 (0.60-0.80); pooled positive likelihood ratio (LR+), 2.92 (2.09-4.09); pooled negative likelihood ratio (LR-), 0.21 (0.14-0.31); pooled diagnostic odds ratio (DOR), 14.08 (7.93-25.01), respectively. Positive predictive values ranged from 0.54 to 0.97 and negative predictive values ranged from 0.26 to 0.92.
CONCLUSION: Currently available evidence indicates that PI-RADS V2 appears to have good diagnostic accuracy in patients with PCa lesions with high sensitivity and moderate specificity. However, no recommendation regarding the best threshold can be provided because of heterogeneity. KEY POINTS: • PI-RADS V2 shows good diagnostic accuracy for PCa detection. • Initially pooled specificity of PI-RADS v2 remains moderate. • PCa detection is increased by experienced radiologists. • There is currently a high heterogeneity in prostate diagnostics with MRI.

Entities:  

Keywords:  Diagnosis; Magnetic resonance imaging; Meta-analysis; PI-RADS V2; Prostate cancer

Mesh:

Year:  2017        PMID: 28656462     DOI: 10.1007/s00330-017-4843-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  31 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

2.  Differentiation of prostatitis and prostate cancer using the Prostate Imaging-Reporting and Data System (PI-RADS).

Authors:  Michael Meier-Schroers; Guido Kukuk; Karsten Wolter; Georges Decker; Stefan Fischer; Christian Marx; Frank Traeber; Alois Martin Sprinkart; Wolfgang Block; Hans Heinz Schild; Winfried Willinek
Journal:  Eur J Radiol       Date:  2016-04-29       Impact factor: 3.528

3.  Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.

Authors:  Raphaëlle Renard-Penna; Pierre Mozer; François Cornud; Nicolas Barry-Delongchamps; Eric Bruguière; Daniel Portalez; Bernard Malavaud
Journal:  Radiology       Date:  2015-01-19       Impact factor: 11.105

4.  Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

Authors:  Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2015-06-18       Impact factor: 11.105

Review 5.  Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.

Authors:  Jurgen J Fütterer; Alberto Briganti; Pieter De Visschere; Mark Emberton; Gianluca Giannarini; Alex Kirkham; Samir S Taneja; Harriet Thoeny; Geert Villeirs; Arnauld Villers
Journal:  Eur Urol       Date:  2015-02-02       Impact factor: 20.096

6.  Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer.

Authors:  Zarine K Shah; Saba N Elias; Ronney Abaza; Debra L Zynger; Lawrence A DeRenne; Michael V Knopp; Beibei Guo; Ryan Schurr; Steven B Heymsfield; Guang Jia
Journal:  Acad Radiol       Date:  2015-01-08       Impact factor: 3.173

7.  Assessment of PI-RADS v2 for the Detection of Prostate Cancer.

Authors:  Moritz Kasel-Seibert; Thomas Lehmann; René Aschenbach; Felix V Guettler; Mohamed Abubrig; Marc-Oliver Grimm; Ulf Teichgraeber; Tobias Franiel
Journal:  Eur J Radiol       Date:  2016-01-19       Impact factor: 3.528

8.  Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.

Authors:  Satoshi Washino; Tomohisa Okochi; Kimitoshi Saito; Tsuzumi Konishi; Masaru Hirai; Yutaka Kobayashi; Tomoaki Miyagawa
Journal:  BJU Int       Date:  2016-04-01       Impact factor: 5.588

9.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  37 in total

Review 1.  PI-RADS v2: Current standing and future outlook.

Authors:  Clayton P Smith; Barış Türkbey
Journal:  Turk J Urol       Date:  2018-05-01

Review 2.  Developing a National Center of Excellence for Prostate Imaging.

Authors:  Annerleim Walton-Diaz; Manuel Madariaga-Venegas; Nicolas Aviles; Juan Carlos Roman; Ivan Gallegos; Mauricio Burotto
Journal:  Curr Urol Rep       Date:  2019-09-02       Impact factor: 3.092

Review 3.  Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?

Authors:  Samuel A Gold; Graham R Hale; Jonathan B Bloom; Clayton P Smith; Kareem N Rayn; Vladimir Valera; Bradford J Wood; Peter L Choyke; Baris Turkbey; Peter A Pinto
Journal:  World J Urol       Date:  2018-05-21       Impact factor: 4.226

4.  Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?

Authors:  Lars A R Reisæter; Ole J Halvorsen; Christian Beisland; Alfred Honoré; Karsten Gravdal; Are Losnegård; Jan Monssen; Lars A Akslen; Martin Biermann
Journal:  Radiol Imaging Cancer       Date:  2020-01-17

5.  Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI.

Authors:  Matthew D Greer; Joanna H Shih; Nathan Lay; Tristan Barrett; Leonardo Bittencourt; Samuel Borofsky; Ismail Kabakus; Yan Mee Law; Jamie Marko; Haytham Shebel; Maria J Merino; Bradford J Wood; Peter A Pinto; Ronald M Summers; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2019-03-27       Impact factor: 3.959

6.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

7.  When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy.

Authors:  Christopher S Lim; Jorge Abreu-Gomez; Michel-Alexandre Leblond; Ivan Carrion; Danny Vesprini; Nicola Schieda; Laurence Klotz
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

8.  Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.

Authors:  Mehdi Taghipour; Alireza Ziaei; Francesco Alessandrino; Elmira Hassanzadeh; Mukesh Harisinghani; Mark Vangel; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2019-04

9.  Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.

Authors:  Jorge Abreu-Gomez; Daniel Walker; Tareq Alotaibi; Matthew D F McInnes; Trevor A Flood; Nicola Schieda
Journal:  Eur Radiol       Date:  2020-03-24       Impact factor: 5.315

10.  A PI-RADS-Based New Nomogram for Predicting Clinically Significant Prostate Cancer: A Cohort Study.

Authors:  Yueyue Zhang; Guiqi Zhu; Wenlu Zhao; Chaogang Wei; Tong Chen; Qi Ma; Yongsheng Zhang; Boxin Xue; Junkang Shen
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.